With improvement in front-line trauma care, efficiency of medical evacuation on the battlefield, and widespread use of body armor, the rate of battlefield mortality has decreased significantly, with increasing numbers of soldiers surviving combat injuries. However, bacterial infections have become increasingly common among military personnel wounded in Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF). Perhaps more alarming are the recent reports that >80% of clinical isolates from military medical treatment facilities are resistant to >3 different classes of antimicrobial drugs. To address the challenge of detecting and identifying myriad sources of resistance, we have developed the Antimicrobial Resistance Determinant Microarray (ARDM) to provide DNA-based analysis for 278 resistance genes covering 12 classes of antibiotics. In collaboration with Walter Reed Army Institute of Research and Naval Medical Research Unit-3 Cairo, we are validating ARDM and refining content of future iterations to improve sensitivity, selectivity, and redundancy to target the pathogenic species most common to war trauma-associated infection and important emerging resistance mechanisms. ARDM is also being used to track changes in genetic resistance profiles over time in wound isolates from OIF/OEF patients in an effort to identify trends of new and emerging resistance markers. We anticipate that ARDM will provide a valuable tool for broad-spectrum, unbiased, and validated determination of antimicrobial resistances that will be useful in guiding medical personnel towards therapeutic strategies most likely to be effective.